Status:
RECRUITING
Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Postoperative Nausea and Vomiting
Dexamethasone Palmitate
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preop...
Eligibility Criteria
Inclusion
- Aged 18 to 65 years;
- Providing written informed consent;
- Patients scheduled to undergo elective minimally invasive endoscopic surgery (laparoscopic or thoracoscopic surgery) under general anaesthesia.
Exclusion
- Known to be allergic to dexamethasone;
- Any systemic glucocorticoids within 3 months before trial entry;
- History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);
- Cognitive impairment or severe mental illness;
- Uncontrolled diabetes or infectious diseases;
- Pregnancy or breastfeeding.
Key Trial Info
Start Date :
June 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
588 Patients enrolled
Trial Details
Trial ID
NCT06981754
Start Date
June 17 2025
End Date
December 31 2026
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China, 100070